A Therapeutic Equivalent to SOMATULINE® DEPOT*
Lanreotide Injection
120 mg/0.5 mL
| DETAILS |
|---|
| NDC | 69097-906-67 |
| STRENGTH | 120 mg/0.5 mL |
| RLD | Somatuline® Depot* |
| TE Rating | AB |
| SELLING UNIT | 1 |
| SELLING UNITS PER SHIPPING CASE | 20 |
| STORAGE | 2°C to 8°C (36°F to 46°F) Protect from light |
| SHELF LIFE | 18 months |
*Somatuline® Depot is a registered trademark of Ipsen Pharma S.A.S.
A Therapeutic Equivalent to SOMATULINE® DEPOT*
Lanreotide Injection
120 mg/0.5 mL
69097-906-67
AB
Protect from light
18 months
*Somatuline® Depot is a registered trademark of Ipsen Pharma S.A.S.
Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
Please see Important Safety Information below
Lanreotide Injection
120 mg/0.5 mL
Product Overview Sheet
Looking for a print-friendly version of Lanreotide Injection information for health care providers?
Download our Product Overview sheet to share with your colleagues. Please click here to contact us if you have any questions about Lanreotide Injection.
Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
Please see Important Safety Information below
Lanreotide Injection
120 mg/0.5 mL
Product Overview Sheet
Looking for a print-friendly version of Lanreotide Injection information for health care providers?
Download our Product Overview sheet to share with your colleagues. Please click here to contact us if you have any questions about Lanreotide Injection.
Packaging Information
Dosing & Administration
Before administering Lanreotide Injection 120mg, it’s important for healthcare providers to know what to expect in each box and how to properly inject the medication. This medication should be administered under the supervision of a healthcare professional and must be left at room temperature for 30 minutes before administration.
Each Lanreotide Injection 120 mg/0.5 mL box contains:
- One prefilled syringe containing 120mg of Lanreotide
- Instructions for Use Leaflet
Please refer to the Important Safety Information or the accompanying full Prescribing Information which includes additional Important Safety Information as well as the Instructions for Use.
Packaging Information
Dosing & Administeration
Before administering Lanreotide Injection 120mg, it’s important for healthcare providers to know what to expect in each box and how to properly inject the medication.
This medication should be administered under the supervision of a healthcare professional and must be left at room temperature for 30 minutes before administration.
Each Lanreotide Injection 120 mg/0.5 mL box contains:
- One prefilled syringe containing Lanreotide 120 mg (provided as Lanreotide acetate)
- Instructions for Use Leaflet
Please refer to the Important Safety Information or the accompanying full Prescribing Information which includes additional Important Safety Information as well as the Instructions for Use.
Interested in ordering directly from Cipla? Please fill out the form below.
| WHOLESALER/DISTRIBUTOR ORDER ENTRY NUMBER |
|---|
| CENCORA | MCKESSON |
| 10289332 | 2906519 |
WANT TO LEARN MORE ABOUT
LANREOTIDE INJECTION
120 mg/0.5 mL
WANT TO LEARN MORE ABOUT
LANREOTIDE INJECTION
120 mg/0.5 mL
Important Safety Information
Please Read Before Administration
Contraindications:
Hypersensitivity to lanreotide.
Warnings and Precautions
Cholelithiasis and Complications of Cholelithiasis: Monitor patients periodically discontinue if complications of cholelithiasis are suspected. Gallstones may occur; consider periodic monitoring.
Hyperglycemia and Hypoglycemia: Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly.
Most Common Adverse Reactions (>10%) include abdominal pain, musculoskeletal pain, vomiting, headache, injection site reaction, hyperglycemia, hypertension, and cholelithiasis.
Immunogenicity: There is potential for immunogenicity.
Drug Interactions
Insulin and Oral Hypoglycemic Drugs: Blood glucose levels should be monitored and antidiabetic treatment should be adjusted accordingly.
Cyclosporine: Lanreotide Injection may decrease the absorption of cyclosporine. Dosage adjustment of cyclosporine may be needed.
Bromocriptine: Lanreotide may increase the absorption of bromocriptine.
Bradycardia-Inducing Drugs (e.g., beta-blockers): Lanreotide Injection may decrease heart rate. Dosage adjustment of the coadministered drug may be necessary.
Drug Metabolism Interactions: Avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine). Drugs metabolized by the liver may be metabolized more slowly during Lanreotide Injection treatment; dose reductions of the concomitantly administered medications should be considered.
Use in Specific Populations
Pregnancy: The risk of major birth defects and miscarriage is unknown.
Lactation: Advise women not to breastfeed during treatment with Lanreotide Injection and for 6 months following the last dose.
Females and Males of Reproductive Potential: Lanreotide Injection may reduce fertility in females of reproductive potential.
Geriatric Use: Dose selection for an elderly patient should be cautious.
You may report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch. You may also report side effects to Cipla at 1-866-604-3268.
Please see the full Prescribing Information for additional Important Safety Information.
Important Safety Information
Please Read Before Administration
Indications
Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
Important Safety Information
Contraindications: Hypersensitivity to lanreotide.
Warnings and Precautions
Cholelithiasis and Complications of Cholelithiasis: Monitor patients periodically. Discontinue if complications of Cholelithiasis are suspected. Gallstones may occur; consider periodic monitoring.
Hyperglycemia and Hypoglycemia: Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly.
Most Common Adverse Reactions (>10%) include abdominal pain, musculoskeletal pain, vomiting, headache, injection site reaction, hyperglycemia, hypertension, and cholelithiasis.
Immunogenicity: There is potential for immunogenicity.
Drug Interactions
Insulin and Oral Hypoglycemic Drugs: Blood glucose levels should be monitored and antidiabetic treatment should be adjusted accordingly.
Cyclosporine: Lanreotide Injection may decrease the absorption of cyclosporine. Dosage adjustment of cyclosporine may be needed.
Bromocriptine: Lanreotide may increase the absorption of bromocriptine.
Bradycardia-Inducing Drugs (e.g., beta-blockers): Lanreotide Injection may decrease heart rate. Dosage adjustment of the coadministered drug may be necessary.
Drug Metabolism Interactions: Avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine). Drugs metabolized by the liver may be metabolized more slowly during Lanreotide Injection treatment; dose reductions of the concomitantly administered medications should be considered.
Use in Specific Populations
Pregnancy: The risk of major birth defects and miscarriage is unknown.
Lactation: Advise women not to breastfeed during treatment with Lanreotide Injection and for 6 months following the last dose.
Females and Males of Reproductive Potential: Lanreotide Injection may reduce fertility in females of reproductive potential.
Geriatric Use: Dose selection for an elderly patient should be cautious.
You may report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch. You may also report side effects to Cipla at 1-866-604-3268.
Please see the full Prescribing Information for additional Important Safety Information.
